Trial
NCT02284906
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Takeda
Collaborators
—
Condition
Mild Cognitive Impairment Due to Alzheimer's Disease
Intervention
Pioglitazone
Why stopped
Lack of efficacy of the drug; no safety concern
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-07-02